By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Celltrion Healthcare (Formerly Known As Celltrion) 

1000 Marina Boulevard
Suite 200
Brisbane  California  94005  U.S.A.
Phone: N/A Fax:


SEARCH JOBS

Celltrion Healthcare conducts the worldwide marketing, sales and distribution of biological medicines developed by Celltrion, Inc. through an extensive global network that spans more than 120 different countries. Celltrion Healthcare’s products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US Food and Drug Administration (FDA) cGMP guidelines and the EU GMP guidelines.

YEAR FOUNDED:

1999

LEADERSHIP:

CEO: Jung Jini

CLINICAL TRIAL:

Please click here for clinical trial information.

PRODUCTS:

All Products

FOLLOW CELLTRION:




Key Statistics


Email: sshong@celltrion.com
Ownership: Public

Web Site: Celltrion Healthcare
Employees:
Symbol: 068270.KQ
 



Industry
Biotechnology






Company News
Celltrion Healthcare (068270.KQ) Release: Truxima, The First Biosimilar Mab In Oncology, Granted EU Marketing Authorization 2/22/2017 6:41:23 AM
Celltrion Healthcare (068270.KQ) Releases Positive Results From Pivotal Study In Crohn’s Disease 2/17/2017 10:59:05 AM
Celltrion Healthcare (068270.KQ) Release: New Statement From European Crohn's And Colitis Organisation Supports Switching To Biosimilar From Reference Product In Inflammatory Bowel Disease 12/9/2016 11:12:23 AM
Celltrion Healthcare (068270.KQ) Presents Positive Results For CT-P10, Biosimilar Rituximab Candidate, In Newly Diagnosed Advanced Stage Follicular Lymphoma 12/5/2016 12:54:27 PM
Celltrion Healthcare (068270.KQ) Showcases Data Supporting Efficacy And Safety Of Both CT-P10 And CT-P13 Biosimilars 11/14/2016 11:54:41 AM
Week In Review: Teva (TEVA) Pays $160 Million For US/Canada Rights To Celltrion (068270.KQ) Biosimilars 10/10/2016 9:19:29 AM
Teva (TEVA) Pays $160 Million to Celltrion (068270.KQ) in Biosimilar Hook-Up 10/6/2016 7:03:59 AM
Celltrion (068270.KQ) Announces Its Commitment To Develop Anti-Drug Antibody And Drug Concentration Assay To Enable Evidence-Based Decision-Making In anti-TNF Treatment 7/5/2016 11:23:45 AM
FDAAdvisoryCommittee.com Approves Celltrion (068270.KQ)’s INFLECTRA, the First Cheaper Version of Johnson & Johnson (JNJ) Blockbuster Remicade 4/6/2016 6:19:31 AM
FDA’s Arthritis Advisory Committee Recommends Approval Of Celltrion (068270.KQ)’s CT-P13, A Proposed Biosimilar Infliximab, For All Indications 2/10/2016 11:05:25 AM
1234
//-->